Southeast Asian Brugada Syndrome Cohort

Discovering the Genetic Causes of Brugada Syndrome in Thais and Southeast Asian Population

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04232787

Acronym

SEA-BrS

Enrollment

750

Registered

2020-01-18

Start date

2016-01-28

Completion date

2023-01-31

Last updated

2020-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brugada Syndrome

Keywords

Brugada Syndrome, Genetics, Epidemiology, Thai, Southeast Asia

Brief summary

Brugada syndrome (BrS) is the leading cause of sudden death in young Asian adults including Thailand. This syndrome may be hereditary and involve mutations in certain genes. Aim of the study is to identify the relationship between genetic variants and the diagnosis/clinical severity of patients with BrS.

Detailed description

This cohort study recruits BrS patients with confirmed Brugada type 1 ECG and healthy volunteers in Thailand. Data collection consists of demographic, clinical data, ECG and blood sample for genetic studies. Genotyping was done by whole genome sequencing and SNP array then compared between cases and controls. Each BrS patient will be followed up prospectively for symptoms and AICD shock. Subsequently, the study will analyze relationship between genetic variants and clinical data against clinical severity of BrS patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Thai nationality * The patient has at least one of confirmed Brugada type 1 ECG in at least one of right precordial leads (v1 or v2) with or without pharmacologic provocative testing. The confirmed ECG is standard 12 lead ECG or Brugada lead

Exclusion criteria

* The patient has other cardiac diseases such as ischemic heart disease, valvular heart disease, congenital heart disease, myocarditis and pericarditis * The patient has type 2 or type 3 Brugada ECG without type 1 ECG during pharmacologic provocative testing and/or Brugada lead * The patient had one time of Brugada type 1 ECG during drug use without reproducibility

Design outcomes

Primary

Measure	Time frame	Description
Relationship between genetic variants and Brugada syndrome (Brugada syndrome phenotype)	7 years	Case-Control study of genetic variants in BrS cases vs controls. Genetic study was done by whole genome sequencing and SNP array. Association analysis assessed by polygenic risk score and regression coefficients.

Secondary

Measure	Time frame	Description
Natural history of Brugada syndrome (survival from arrhythmic events)	7 years	Cohort study to followed up BrS patients with or with arrhythmic events which assessed by survival curve analysis.
Epidemiology of Brugada syndrome	7 years	To study prevalence of Brugada syndrome in Thailand.

Countries

Thailand

Contacts

Primary ContactApichai Khongphatthanayothin, MD

apichaik@yahoo.com66891555545

Backup ContactPharawee Wandee, BSc

brugadaproject@gmail.com66944174331

Outcome results